Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Nienhuis

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 7, 2007
Troponin T elevation and prognosis after multivessel compared with single-vessel elective percutaneous coronary interventionM B Nienhuis, J P Ottervanger, J-H E Dambrink, et al.
American Heart Journal|April 24, 2012
DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers populationKenneth Tandjung, Mounir W Z Basalus, Hanim Sen, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 24, 2011
Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stentsKenneth Tandjung, Mounir W Z Basalus, Esther Muurman, et al.
Annals of Clinical Biochemistry|July 11, 2006
Predictors of elevated cardiac troponin T on admission in ST-segment elevation myocardial infarctionSaman Rasoul, Mark B Nienhuis, Jan Paul Ottervanger, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 8, 2014
Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trialMing Kai Lam, Kenneth Tandjung, Hanim Sen, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 15, 2012
Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stentsHanim Sen, Kenneth Tandjung, Mounir W Z Basalus, et al.
The American Journal of Cardiology|September 4, 2012
Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial)Kenneth Tandjung, K Gert van Houwelingen, Hanneke Jansen, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2014
Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trialHanim Sen, Ming Kai Lam, Kenneth Tandjung, et al.
Journal of the American College of Cardiology|April 23, 2013
Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trialKenneth Tandjung, Hanim Sen, Ming Kai Lam, et al.
Lancet (London, England)|November 5, 2013
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trialClemens von Birgelen, Hanim Sen, Ming Kai Lam, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 7, 2007
Troponin T elevation and prognosis after multivessel compared with single-vessel elective percutaneous coronary interventionM B Nienhuis, J P Ottervanger, J-H E Dambrink, et al.
American Heart Journal|April 24, 2012
DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers populationKenneth Tandjung, Mounir W Z Basalus, Hanim Sen, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 24, 2011
Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stentsKenneth Tandjung, Mounir W Z Basalus, Esther Muurman, et al.
Annals of Clinical Biochemistry|July 11, 2006
Predictors of elevated cardiac troponin T on admission in ST-segment elevation myocardial infarctionSaman Rasoul, Mark B Nienhuis, Jan Paul Ottervanger, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 8, 2014
Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trialMing Kai Lam, Kenneth Tandjung, Hanim Sen, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 15, 2012
Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stentsHanim Sen, Kenneth Tandjung, Mounir W Z Basalus, et al.
The American Journal of Cardiology|September 4, 2012
Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial)Kenneth Tandjung, K Gert van Houwelingen, Hanneke Jansen, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2014
Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trialHanim Sen, Ming Kai Lam, Kenneth Tandjung, et al.
Journal of the American College of Cardiology|April 23, 2013
Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trialKenneth Tandjung, Hanim Sen, Ming Kai Lam, et al.
Lancet (London, England)|November 5, 2013
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trialClemens von Birgelen, Hanim Sen, Ming Kai Lam, et al.
Pageof 5